Saturated free fatty acids (FFAs) act as lipid mediators and induce insulin resistance in skeletal muscle. Specifically, in obesityârelated diseases such as type 2 diabetes, FFAs directly reduce insulin sensitivity and glucose uptake in skeletal muscle. However, the knowledge of how FFAs mediate inflammation and subsequent tissue disorders, including fibrosis in skeletal muscle, is limited. FFAs are a natural ligand for tollâlike receptor 2 (TLR2) and TLR4, and induce chronic lowâgrade inflammation that directly stimulates skeletal muscle tissue. However, persistent inflammatory stimulation in tissues could induce proâfibrogenic processes that ultimately lead to perturbation of the tissue architecture and dysfunction. Therefore, blocking the link between inflammatory primed skeletal muscle tissue and connective tissue might be an efficient therapeutic option for treating obesityâinduced muscle inactivity. In this study, we investigated the impact of conditioned medium obtained from human palatine tonsilâderived mesenchymal stem cells (TâMSCs) on the interaction between skeletal muscle cells stimulated with palmitic acid (PA) and fibroblasts. We found that PAâtreated skeletal muscle cells actively secreted interleukinâ1ÎČ (ILâ1ÎČ) and augmented the migration, proliferation and expression of fibronectin in L929 fibroblasts. Furthermore, TâCM inhibited the skeletal muscle cellâderived proâfibrogenic effect via the production of the interleukinâ1 receptor antagonist (ILâ1Ra), which is an inhibitor of ILâ1 signalling. Taken together, our data provide novel insights into the therapeutic potential of TâMSCâmediated therapy for the treatment of pathophysiological processes that occur in skeletal muscle tissues under chronic inflammatory conditions.